The Worldwide Market for Targeted Cancer Therapeutics

The Worldwide Market for Targeted Cancer Therapeutics

Kalorama Information has watched the cancer treatment market evolve over the past two decades and evaluated the impact new technologies are making on the market. Worldwide Market for Targeted Cancer Therapeutics focuses on the expanding area of targeted therapies and includes current products available and discusses some of the most exciting developments in progress. This report covers targeted cancer therapies that do at least one of the following:

• Block or turn off chemical signals that tell the cancer cell to grow and divide
• Change proteins within the cancer cells so the cells die
• Stop making new blood vessels to feed the cancer cells
• Trigger the immune system to kill the cancer cells
• Carry toxins to the cancer cells to kill them, but not normal cells

This report on the targeted cancer therapeutics market specifically focuses on five leading segments of targeted therapies – monoclonal antibodies, tyrosine kinase inhibitors, angiogenesis inhibitors, CDK inhibitors, and proteasome inhibitors – providing information on a global level, including:

• Global Targeted Cancer Therapeutic Market Size and Forecast, 2010-2025 ($millions) (monoclonal antibodies, tyrosine kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CDK inhibitors, others)
• Cancer Monoclonal Antibody Market, 2018-2025 ($ millions)
• Top 10 Cancer Indicated Monoclonal Antibodies, 2017 and 2018 Sales (millions $)
• Monoclonal Antibodies in Cancer Therapy (Trade Name, Biological Name, Target, Indication[s])
• Tyrosine Kinase Inhibitor Market, 2018-2025 ($ millions)
• Top 10 Cancer Indicated Tyrosine Kinase Inhibitors, 2017 and 2018 Sales (millions $)
• Tyrosine Kinase Inhibitors in Cancer Therapy (Trade Name, Biological Name, Target, Indication[s])
• Angiogenesis Inhibitor Market, 2018-2025 ($ millions)
• Angiogenesis Inhibitors in Cancer Therapy (Trade Name, Biological Name, Indication[s])
• CDK Inhibitor Market, 2018-2025: ($ millions)
• CDK Inhibitors in Cancer Therapy (Trade Name, Biological Name, Target, Indication[s])
• Proteasome Inhibitor Market, 2018-2025: ($ millions)
• Proteasome Inhibitors in Cancer Therapy (Trade Name, Biological Name, Target, Indication[s])
• Other Targeted Therapies Market, 2018-2025: ($ millions)
• Other Targeted Cancer Therapies (Classification, Trade Name, Biological Name, Target, Indication[s])

The report also provides specific information by type and by target on a global level for the monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKI) segments, including:

• Cancer Monoclonal Antibody Market by Type
• Development of the mAb Cancer Treatment Market, 2010-2025 (Breast Cancer, Colorectal Cancer, Lymphoma, Leukemia, Myeloma, Melanoma, Lung, Renal, Others)
• Monoclonal Antibody Market by Cancer Type, 2018 and 2025 ($ millions) (Breast, Lymphoma, Lung, Colorectal, Melanoma, Multiple Myeloma, Kidney, Leukemia, Ovarian, Urothelial, Head/Neck, GIST, Brain, Sarcoma, Liver, Other Solid Tumors, Other undisclosed/Unknown)
• Monoclonal Antibody Market, Distribution by Cancer Type, 2018 (%) (Breast, Lymphoma, Lung, Colorectal, Melanoma, Multiple Myeloma, Kidney, Leukemia, Ovarian, Urothelial, Head/Neck, GIST, Brain, Sarcoma, Liver, Other Solid Tumors, Other undisclosed/Unknown)
• Monoclonal Antibody Market Distribution by Indication, 2025 (%) (Breast, Lymphoma, Lung, Colorectal, Melanoma, Multiple Myeloma, Kidney, Leukemia, Ovarian, Urothelial, Head/Neck, GIST, Brain, Sarcoma, Liver, Other Solid Tumors, Other undisclosed/Unknown)
• Cancer Tyrosine Kinase Inhibitor Market by Type
• Development of the TKI Cancer Treatment Market, 2010-2025 (Leukemia, Lung, Lymphoma, Kidney, Melanoma, GIST, Liver, Pancreatic, Breast, Thyroid, Colorectal, Other)
• TKI Market by Cancer Indication, 2018 and 2025 ($ millions) (Leukemia, Lung, Lymphoma, Kidney, Melanoma, GIST, Liver, Pancreatic, Breast, Thyroid, Colorectal, Other)
• TKI Market Distribution by Cancer Indication, 2018 (%) (Leukemia, Lung, Lymphoma, Kidney, Melanoma, GIST, Liver, Pancreatic, Breast, Thyroid, Colorectal, Other)
• TKI Market Distribution by Cancer Indication, 2025 (%) (Leukemia, Lung, Lymphoma, Kidney, Melanoma, GIST, Liver, Pancreatic, Breast, Thyroid, Colorectal, Other)
• Cancer Monoclonal Antibody Market by Target
• Cancer Monoclonal Antibody Market by Target, 2018 and Forecast 2025 ($ millions) (PD-1, HER2, VEGF, CD20, EGFR, CD38, RANKL, CTLA-4, PD-L1, CD30, PDGF)
• Cancer Monoclonal Antibody Market Distribution by Target, 2018 (%) (PD-1, HER2, VEGF, CD20, EGFR, CD38, RANKL, CTLA-4, PD-L1, CD30, PDGF)
• Cancer Monoclonal Antibody Market Distribution by Target, 2025 (%) (PD-1, HER2, VEGF, CD20, EGFR, CD38, RANKL, CTLA-4, PD-L1, CD30, PDGF)
• Cancer Tyrosine Kinase Inhibitor Market by Target
• Cancer TKI Market by Target, 2018 and Forecast 2025 ($ millions) (Single Target: ALK, ABL, BTK, EGFR, VEGF, HER2, BRAF, Others; Multi-target)
• TKI Market Distribution by Target, 2018 (%) (ALK, ABL, BTK, EGFR, VEGF, HER2, BRAF, Others; Multi-target)
• TKI Market Distribution by Target, 2025 (%) (ALK, ABL, BTK, EGFR, VEGF, HER2, BRAF, Others; Multi-target)

The United States cancer pharmaceutical industry is the largest in terms of revenues generated. Western European markets are major drivers for innovative cancer treatment markets with growing sales in emerging Eastern European markets. Asia Pacific sales are driven by established economies such as Japan and Australia and emerging markets such as China. Cancer treatment markets have been slower to develop in Latin American markets, with targeted therapies often secondary to traditional chemotherapy or hormone therapy. Worldwide Market for Targeted Cancer Therapeutics provides regional market overviews, encompassing United States and Canada; Europe, Middle East and Africa (EMEA); Asia Pacific; and Latin America:

• Targeted Cancer Therapeutics Market Summary by Geographical Region, 2018-2025 ($ millions) (United States and Canada; Europe, Middle East, Africa (EMEA); Asia Pacific; Latin America; Global Market)
• United States and Canada
• Targeted Cancer Therapeutics Market Summary for U.S. and Canada, 2018-2025 ($ millions) (Monoclonal antibodies, Tyrosine kinase inhibitors, Angiogenesis Inhibitors, Proteasome inhibitors, CDK inhibitors, Other targeted therapies, Total)
• Targeted Cancer Therapeutics for U.S. and Canada, Distribution by Therapy Type (monoclonal antibodies, tyrosine kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CDK inhibitors, other targeted therapies), 2018 %
• EMEA
• Targeted Cancer Therapeutics Market Summary for EMEA, 2018-2025 ($ millions) (Monoclonal antibodies, Tyrosine kinase inhibitors, Angiogenesis Inhibitors, Proteasome inhibitors, CDK inhibitors, Other targeted therapies, Total)
• Targeted Cancer Therapeutics for EMEA, Distribution by Therapy Type (monoclonal antibodies, tyrosine kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CDK inhibitors, other targeted therapies), 2018 %
• Asia Pacific
• Targeted Cancer Therapeutics Market Summary for Asia Pacific, 2018-2025 ($ millions) (Monoclonal antibodies, Tyrosine kinase inhibitors, Angiogenesis Inhibitors, Proteasome inhibitors, CDK inhibitors, Other targeted therapies, Total)
• Targeted Cancer Therapeutics for Asia Pacific, Distribution by Therapy Type (monoclonal antibodies, tyrosine kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CDK inhibitors, other targeted therapies), 2018 %
• Latin America
• Targeted Cancer Therapeutics Market Summary for Latin America, 2018-2025 ($ millions) (Monoclonal antibodies, Tyrosine kinase inhibitors, Angiogenesis Inhibitors, Proteasome inhibitors, CDK inhibitors, Other targeted therapies, Total)
• Targeted Cancer Therapeutics for Latin America, Distribution by Therapy Type (monoclonal antibodies, tyrosine kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CDK inhibitors, other targeted therapies), 2018 %

The report includes competitive summaries of the leading market providers. In addition, the report provides competitor market share in major market segments, including:

• Cancer Monoclonal Antibody Competitor Market Share - Top Seven, 2018 ($ millions)
• Cancer TKI Competitor Market Share, 2018 ($ millions)
• Cancer CDK Inhibitors Competitor Market Share, 2018 ($ millions)
• Cancer Proteasome Inhibitor Competitor Market Share, 2018 ($ millions)

Worldwide Market for Targeted Cancer Therapeutics concludes with profiles of the leading competitors in the targeted cancer therapeutic market, including:

• AbbVie, Inc.
• Adaptimmune Therapeutics plc.
• Advantagene, Inc.
• Agenus, Inc.
• Amgen
• Anchiano Therapeutics
• Apceth Biopharma GmbH & Co. KG
• Apollomics, Inc.
• Aptevo Therapeutics
• AstraZeneca PLC
• Aurobindo Pharma Ltd.
• Bayer AG
• Bellicum Pharmaceuticals, Inc.
• Biocon Ltd
• BioInvent International AB
• bluebird bio, Inc.
• Boehringer Ingelheim
• Bristol-Myers Squibb Company
• Celgene Corporation
• Celldex Therapeutics
• Celltrion, Inc.
• Celsion Corporation
• Clovis Oncology, Inc.
• Cold Genesys, Inc.
• Dendreon Pharmaceuticals LLC
• Eisai Co., Ltd.
• Eli Lilly & Company
• EMD Serono, Inc. (Merck KgaA)
• Exelixis, Inc.
• Gamida Cell Ltd.
• Genprex, Inc.
• Gilead Sciences, Inc.
• Immunomedics, Inc.
• Incyte Corporation
• Innate Pharma S.A.
• Inovio Pharmaceuticals, Inc.
• Johnson & Johnson
• MacroGenics, Inc.
• Merck & Co., Inc.
• Merrimack Pharmaceuticals, Inc.
• Nascent Biotech
• Northwest Biotherapeutics, Inc.
• Novartis AG
• Oncolytics Biotech, Inc.
• OncoMed Pharmaceuticals, Inc.
• OncoSec Medical, Inc.
• Oncternal Therapeutics
• Otsuka Holdings Co., Ltd.
• Pfizer, Inc.
• Puma Biotechnology, Inc.
• Regeneron Pharmaceuticals
• Roche (F. Hoffman-La Roche, Ltd.)
• Sanofi
• Seattle Genetics, Inc.
• Sesen Bio
• Sorrento Therapeutics
• Takeda Oncology - Millennium Pharmaceuticals
• TESARO, Inc.
• TG Therapeutics, Inc.
• Tocagen, Inc.
• Vascular Biogenics Ltd.
• ZIOPHARM Oncology, Inc.